Dermapharm is a rapidly growing manufacturer of branded pharmaceuticals. Founded in 1991, the Company is based in Grünwald near Munich. The Company's integrated business model comprises in-house development, production and the distribution of brand products by a trained pharmaceutical sales force. In addition to its main location in Brehna near Leipzig, Dermapharm also operates other production, development and distribution locations in Europe (primarily in Germany) and the United States.
In the "Branded pharmaceuticals and other healthcare products" segment, Dermapharm has approximately 1,300 marketing authorisations with more than 380 active pharmaceutical ingredients. Dermapharm's portfolio of pharmaceuticals, medical devices and food supplements are tailored to selected therapeutic areas in which the Company is a market leader, especially in Germany.
1991
Served areaEurope + North America
Headcount2,373
HeadquartersLil-Dagover-Ring 7, 82031 Grünwald – Germany
Date | Trading entity / Person | Association | Trade type | Volume | Average price |
---|---|---|---|---|---|
13.01.23 | NEON Equity AG | Close relation | Buy | 16,897.00 € | 13.01.23 |
11.01.23 | Dreibholz, Christof | Board | Buy | 49,638.00 € | 11.01.23 |
17.10.22 | Riedel, Oliver | Board | Buy | 8,650.00 € | 17.10.22 |
17.10.22 | Weidenmann, Ralph | Supervisory board | Buy | 2,638.25 € | 17.10.22 |
17.10.22 | Riedel, Oliver | Board | Buy | 11,013.18 € | 17.10.22 |
14.10.22 | Feldmeier, Dr. Hans-Georg | Board | Buy | 98,900.00 € | 14.10.22 |
13.10.22 | Themis Beteiligungs-Aktiengesellschaft | Close relation | Buy | 55,825,000.00 € | 13.10.22 |
13.10.22 | Kellinghusen, Dr. Georg | Supervisory board | Buy | 4,884.80 € | 13.10.22 |
22.07.21 | Neumeyer, Hilde | Board | Buy | 163,938.30 € | 22.07.21 |
22.07.21 | Wahl, Dr. Albert | Board | Buy | 8,514.00 € | 22.07.21 |
53,840,000
IPOFeb. 9, 2018
Designated Sponsor(s)Stifel Europe Bank AG, Joh. Berenberg, Gossler & Co. KG
Stock exchange(s)Frankfurt Stock Exchange